Aortic Center, CHRU, Lille, France.
Service de Chirurgie Vasculaire, CHU de Nancy, Nancy, France.
J Vasc Surg. 2018 Mar;67(3):685-693. doi: 10.1016/j.jvs.2017.09.010. Epub 2017 Nov 15.
We report our experience of the treatment of postdissection arch aneurysms and thoracoabdominal aortic aneurysms (TAAAs) by endovascular repair using fenestrated and branched endografts.
This study includes all patients presenting with chronic postdissection aneurysms >55 mm in diameter deemed unfit for open surgery and treated by complex endografting between October 2011 and April 2017. Where appropriate, staged management strategies including left subclavian artery revascularization, thoracic endografting, dissection flap fenestration, and tear enlargement were performed before the complex endovascular repair. Outcome data were collected prospectively, specifically including technical success, endoleaks, target vessel patency, aneurysm diameter, adverse events, reinterventions, and mortality.
We treated 40 patients with a median age of 63 years (55-71 years). In total, 43 procedures were performed: 19 arch repairs using inner branch endografts (one to three branches) and 24 TAAA repairs using fenestrated or branched endografts. Three patients were treated using both arch and TAAA repair. The median time between initial presentation with acute dissection and the first complex aortic repair was 5 years (3.0-10.0 years). Staged procedures were performed in 33 of 40 patients (82.5%). The technical success rate was 93%, the median procedure length was 240 minutes (170-285 minutes), and the median dose-area product was 80 Gy · cm (54.3-138.4 Gy · cm). The 30-day and in-hospital mortality rates were 2.3% (1/43) and 4.7% (2/43), respectively. The spinal cord ischemia rate was 7% and occurred only after TAAA repair. One stroke with partial recovery and one transient ischemic attack were observed (4.7%) after arch repair. Six early reinterventions (14%) were performed: three for access complications, two to treat acute hemorrhage, and one to treat a type II endoleak. Median follow-up was 25.5 months (11-42.25 months). The 1- and 5-year survival rates were 90% and 76.4%, respectively. Late reinterventions were required in eight patients, two in the arch group (to treat endoleaks at 3 and 33 months) and six in the TAAA group (2 iliac and 1 bifurcated endograft extensions, 2 additional renal stents, 1 inferior mesenteric artery embolization). Aneurysm diameter was stable (72%) or shrank (23%) during follow-up. Enlargement was shown in two patients with endoleaks.
Complex endovascular repair of postdissection aneurysms is a safe procedure in patients deemed unfit for open surgery. Our experience suggests that close follow-up is mandatory as secondary procedures are frequently required to completely exclude the false lumen.
我们报告了使用开窗和分支内植物进行血管内修复治疗夹层弓部动脉瘤和胸腹主动脉瘤(TAAA)的经验。
本研究包括所有 2011 年 10 月至 2017 年 4 月期间因不适合开放手术而接受复杂内植物治疗的慢性夹层后直径>55mm 的大动脉瘤患者。在适当的情况下,包括左锁骨下动脉再血管化、胸主动脉内支架植入、夹层瓣开窗和撕裂扩大等分期管理策略在复杂血管内修复前进行。前瞻性收集了包括技术成功率、内漏、靶血管通畅性、动脉瘤直径、不良事件、再干预和死亡率在内的结果数据。
我们治疗了 40 例中位年龄为 63 岁(55-71 岁)的患者。共进行了 43 次手术:19 例使用内分支内植物进行弓部修复(1-3 个分支),24 例使用开窗或分支内植物进行 TAAA 修复。3 例患者同时接受弓部和 TAAA 修复。初次急性夹层表现与首次复杂主动脉修复之间的中位时间为 5 年(3.0-10.0 年)。40 例患者中有 33 例(82.5%)进行了分期手术。技术成功率为 93%,中位手术时间为 240 分钟(170-285 分钟),中位剂量面积积分为 80Gy·cm(54.3-138.4Gy·cm)。30 天和住院死亡率分别为 2.3%(1/43)和 4.7%(2/43)。脊髓缺血率为 7%,仅发生在 TAAA 修复后。观察到 1 例脑卒中伴部分恢复和 1 例短暂性脑缺血发作(4.7%),均发生在弓部修复后。早期需要进行 6 次再干预(14%):3 次用于治疗入路并发症,2 次用于治疗急性出血,1 次用于治疗 II 型内漏。中位随访时间为 25.5 个月(11-42.25 个月)。1 年和 5 年的生存率分别为 90%和 76.4%。8 例患者需要进行晚期再干预,其中 2 例在弓部组(分别在术后 3 个月和 33 个月治疗内漏),6 例在 TAAA 组(2 例髂内和 1 例分叉内植物延伸,2 例额外的肾支架,1 例肠系膜下动脉栓塞)。在随访期间,动脉瘤直径稳定(72%)或缩小(23%)。在 2 例存在内漏的患者中显示出增大。
在不适合开放手术的患者中,复杂的血管内修复治疗夹层后动脉瘤是一种安全的方法。我们的经验表明,需要密切随访,因为通常需要进行二次手术以完全排除假腔。